drugset / Trial / NCT04912167

The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction

NCT04912167 ↗

Phase 3 Unknown 376 enrolled West China Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

The primary objective of the PERI-STEMI trial is to assess whether sacubitril-valsartan is more effective in preventing adverse LV remodeling for patients with ST-elevation myocardial infarction (STEMI) than enalapril.

Timeline

Start
2021-11
Primary completion
2022-03
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enalapril Other / unclassified 2.5 mg —
Comparator Enalapril Other / unclassified 5 mg —
Comparator Enalapril Other / unclassified 10 mg —
Subject Sacubitril-Valsartan Unknown — —
Background Valsartan Unknown 40 mg —
Background Valsartan Unknown 80 mg —